Loading...

SRPT SAREPTA THERAPEUTICS INC Product Launches 8-K Filing

SRPT

SRPT

SAREPTA THERAPEUTICS INC

(SRPT)

2023 8-K

Show Summary

Show Summary

Rights Offerings

Earnings Announcement

Credit Agreement

Financial Results

Collaboration Agreement

Amendment to Incentive Plan

Financial Results

FDA Approval of ELEVIDYS

Annual Meeting Results

External Links:

Sarepta Therapeutics announced FDA approval of ELEVIDYS, a gene therapy for Duchenne muscular dystrophy in pediatric patients aged 4-5 years.

AI Assistant

SAREPTA THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.